1,329 calculators and references across 60 specialties, with formula confidence shown up front.
EchoCRT Non-response Risk Score: Explanation and Clinical Context The EchoCRT Non-response Risk Score was developed from the EchoCRT trial population to predict the likelihood of non-response to cardiac resynchronization therapy (CRT). The model integrates clinical, electrocardiographic, and echocardiographic parameters to stratify patients based on the probability of failing to show symptomatic or reverse remodeling
EFFECT Heart Failure Mortality Score: Explanation and Clinical Context The EFFECT Heart Failure Mortality Score (Enhanced Feedback for Effective Cardiac Treatment) is a validated risk stratification tool developed from a large Canadian cohort to estimate 30-day mortality among patients hospitalized for acute decompensated heart failure. The model incorporates clinical and laboratory variables easily obtained at admis
EJECTION-HF — LVEF Recovery Index (Prototype): explanation and context Left ventricular ejection fraction (LVEF) recovery after an episode of heart failure with reduced ejection fraction (HFrEF) is an important clinical outcome with implications for prognosis and management. Multiple observational studies and systematic reviews show that several features are repeatedly associated with a greater probability of LVEF im
Emergency Heart Failure Mortality Risk Grade (EHMRG): explanation and clinical context The EHMRG is a point-based prognostic model designed to estimate short-term (7-day, and extended 30-day) mortality for patients who present to the emergency department with acute heart failure. It uses data available at ED presentation (age; mode of arrival by EMS; systolic blood pressure; heart rate; peripheral oxygen saturation;
EMPA-REG HF Event Reduction Index: Explanation and Clinical Context The EMPA-REG OUTCOME trial enrolled patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease, randomized to Empagliflozin or placebo, and demonstrated a 35 % relative risk reduction in hospitalization for heart failure (HHF) with empagliflozin. This calculator uses a user-entered estimate of baseline annual risk o
— Explanation and Clinical Context This tool is an approximate, transparent calculator that estimates the expected absolute benefit (absolute risk reduction and number-needed-to-treat) from empagliflozin for the EMPEROR-Preserved primary composite outcome (cardiovascular death or first hospitalization for heart failure) over a follow-up period consistent with the trial (median 26.2 months). The EMPEROR-Preserved rand
: Explanation and Clinical Context The EMPHASIS-HF Mortality Reduction Index is designed to estimate the potential benefit of eplerenone in reducing all-cause mortality among patients with mild to moderate symptomatic heart failure with reduced ejection fraction (HFrEF), as studied in the EMPHASIS-HF trial. The EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) trial demonst
: Explanation and Clinical Context The EMPULSE Response Predictor estimates the likelihood of a favorable clinical outcome with empagliflozin in patients hospitalized for acute heart failure, based on findings from the EMPULSE trial. The trial demonstrated that empagliflozin, initiated in-hospital (median 3 days post-admission), led to significantly higher rates of clinical benefit at 90 days compared to placebo, acr
ENGAGE AF–TIMI 48 HF Subscore: Background, meaning and references The ENGAGE AF–TIMI 48 randomized trial (edoxaban vs warfarin) enrolled over 21,000 patients with atrial fibrillation. A prespecified analysis examined clinical predictors of a composite endpoint of heart-failure hospitalization, death due to heart failure, or sudden cardiac death among patients without a prior history of heart failure. Multivariable Co
References and context The ENTRUST-AF PCI randomized trial and its prespecified analyses inform antithrombotic choices for AF patients undergoing PCI. Key publications: Vranckx P, et al. ENTRUST-AF PCI (Lancet 2019) — trial report; prespecified analyses and subgroup reports are available in subsequent journal publications. Clinicians should combine the trial evidence with individual CHA₂DS₂-VASc and HAS-BLED assessme
: explanation and clinical context This tool implements two things: (1) an objective eligibility check based on the original EPHESUS trial inclusion criteria — specifically enrollment 3–14 days after acute myocardial infarction (MI) with left ventricular ejection fraction (LVEF) ≤40% and either signs/symptoms of heart failure or diabetes — and (2) an exploratory, unvalidated response index that weights several clinic
ESC ICD Primary Prevention Criteria: Explanation and Clinical Context The European Society of Cardiology (ESC) 2022 guidance on ventricular arrhythmias and prevention of sudden cardiac death supports the use of implantable cardioverter-defibrillators (ICDs) for primary prevention in patients with symptomatic heart failure and reduced left ventricular ejection fraction (LVEF) when the patient remains at persistently r
MAGGIC (Meta-Analysis Global Group In Chronic Heart Failure) — explanation and clinical context The MAGGIC prognostic model (Pocock et al., Eur Heart J 2013) was developed from individual-patient data pooled from 39,372 patients across 30 cohorts to predict mortality in chronic heart failure. It uses 13 routinely available clinical variables (age, sex, body mass index, systolic blood pressure, LVEF, serum creatinine,
This integration tool translates the 2023 focused update of the ESC heart failure guidance into a pragmatic bedside checklist and decision aid. It helps clinicians classify phenotype (HFrEF, HFmrEF, HFpEF), check haemodynamic and renal constraints, and assemble the core therapeutic package: ARNI/ACEi/ARB, beta-blocker, MRA, and SGLT2 inhibitors where indicated; use diuretics for congestion; consider specialist referr
ESCAPE Trial Hemodynamic Congestion Index: Rationale, clinical meaning, and evidence The Hemodynamic Congestion Index (HCI) implemented here is the simple sum of right atrial pressure (RAP) and pulmonary capillary wedge pressure (PCWP): HCI = RAP (mmHg) + PCWP (mmHg). This index was derived from analyses of the ESCAPE trial dataset and related secondary analyses that examined whether a single composite invasive press
EUROMACS Right-Sided Heart Failure (RHF) Risk Score: Explanation and Clinical Context The EUROMACS-RHF score is a validated preoperative model derived from the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) to predict early (≤30 days) severe right heart failure after continuous-flow LVAD implantation. It uses five key preoperative variables: RAP/PCWP ratio > 0.54, hemoglobin ≤10 g/dL, ≥
EVEREST HF Prognostic Algorithm — explanation and context The EVEREST score is a 0–18 clinician-rated composite of six symptoms/signs of congestion: dyspnea, orthopnea, fatigue, jugular venous distension (JVD), rales, and pedal edema. Each item is graded 0–3 using the standardized EVEREST grading scale (0 = none; 1 = seldom or mild; 2 = moderate/frequent; 3 = continuous/marked or the numeric JVD/rales/edema threshold